Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
315.69
+0.79 (0.25%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Amgen Revenue
Amgen had revenue of $8.39B in the quarter ending June 30, 2024, with 20.07% growth. This brings the company's revenue in the last twelve months to $30.93B, up 16.37% year-over-year. In the year 2023, Amgen had annual revenue of $28.19B with 7.09% growth.
Revenue (ttm)
$30.93B
Revenue Growth
+16.37%
P/S Ratio
5.46
Revenue / Employee
$1,158,577
Employees
26,700
Market Cap
169.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
Dec 31, 2019 | 23.36B | -385.00M | -1.62% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pfizer | 55.17B |
Sanofi | 50.44B |
Novartis AG | 48.86B |
Thermo Fisher | 42.35B |
Abbott Laboratories | 41.22B |
Danaher | 22.49B |
Stryker | 21.39B |
Boston Scientific | 15.23B |
AMGN News
- 1 hour ago - AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS - PRNewsWire
- 7 hours ago - Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage - GlobeNewsWire
- 2 days ago - Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case - Reuters
- 9 days ago - AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024 - PRNewsWire
- 10 days ago - Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded. - Barrons
- 10 days ago - Amgen's stock falls as analyst warns that hype around obesity drug is baked in - Market Watch
- 16 days ago - The Art of Valuation: Discovering Amgen Inc's Intrinsic Value - GuruFocus
- 18 days ago - Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma - Seeking Alpha